- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07262619
EIK1005-002: Клиническое исследование по оценке EIK1005, ингибитора геликазы Вернера, в качестве монотерапии и в комбинации с пембролизумабом у участников с распространенными солидными опухолями, включая опухоли с высоким уровнем микросателлитной нестабильности (MSI-H)
Многоцентровое, многоэтапное исследование фазы 1/2 препарата EIK1005 в качестве монотерапии и в комбинации с пембролизумабом у участников с распространёнными солидными опухолями, включая участников, наивных к ингибиторам контрольных точек, с опухолями с высокой микросателлитной нестабильностью (MSI-H) или дефицитом репарации неспаренных оснований (dMMR)
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Ana C Mamede, PharmD
- Номер телефона: 347-806-4584
- Электронная почта: mamedea@eikontx.com
Учебное резервное копирование контактов
- Имя: Krishna Kaza
- Электронная почта: kazak@eikontx.com
Места учебы
-
-
New South Wales
-
Saint Leonards, New South Wales, Австралия
- Еще не набирают
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Австралия
- Рекрутинг
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Австралия
- Рекрутинг
- Grampians Health
-
Camperdown, Victoria, Австралия
- Рекрутинг
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Австралия
- Рекрутинг
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Австралия, 3199
- Рекрутинг
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Linz, Австрия, 4020
- Рекрутинг
- Ordensklinikum Linz Elisabethinen
-
-
-
-
-
Brussels, Бельгия, 1020
- Рекрутинг
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Berlin, Германия, 13125
- Рекрутинг
- Helios Klinikum Berlin-Buch
-
Hamburg, Германия, 22297
- Рекрутинг
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Германия, 94469
- Рекрутинг
- DONAUISAR Klinikum
-
-
-
-
-
Barcelona, Испания, 08023
- Рекрутинг
- START - Barcelona
-
Logroño, Испания, 26006
- Рекрутинг
- START Rioja - Hospital de San Pedro
-
Madrid, Испания, 28233
- Рекрутинг
- NEXT Madrid HUQSM
-
Zaragoza, Испания, 50009
- Рекрутинг
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Испания, 07120
- Рекрутинг
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Испания, 8036
- Рекрутинг
- Hospital Clinic Barcelona
-
-
-
-
-
Rome, Италия, 00128
- Рекрутинг
- Campus Bio-Medico di Rome University
-
-
-
-
-
Wellington, Новая Зеландия
- Рекрутинг
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, Новая Зеландия, 4414
- Рекрутинг
- Palmerstone North Hospital
-
-
-
-
-
Oslo, Норвегия, 0379
- Рекрутинг
- Oslo University
-
-
-
-
-
Krakow, Польша, 31-864
- Рекрутинг
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Польша, 90-338
- Рекрутинг
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Польша, 70-419
- Рекрутинг
- One Day Med
-
-
-
-
-
Lisbon, Португалия, 1649-028
- Рекрутинг
- Hospital de Santa Maria
-
Loures, Португалия, 2674-514
- Рекрутинг
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Португалия, 4200
- Рекрутинг
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Португалия, 1500-650
- Рекрутинг
- Hospital da Luz Lisboa
-
-
-
-
-
Singapore, Сингапур, 119074
- Рекрутинг
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Сингапур, 168583
- Рекрутинг
- National Cancer Centre Singapore (NCCS)
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90027
- Рекрутинг
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Соединенные Штаты, 33172
- Рекрутинг
- Omnicure Clinical Research
-
Hialeah, Florida, Соединенные Штаты, 33013
- Рекрутинг
- Bioresearch Partner
-
Plantation, Florida, Соединенные Штаты, 33322
- Рекрутинг
- Florida Clinical Trials Group
-
Tamarac, Florida, Соединенные Штаты, 33321
- Рекрутинг
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Соединенные Штаты, 07960
- Рекрутинг
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Соединенные Штаты, 11042
- Рекрутинг
- START New York-Long Island
-
New York, New York, Соединенные Штаты, 10022
- Рекрутинг
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Рекрутинг
- START Dallas Fort Worth
-
Houston, Texas, Соединенные Штаты, 77030
- Рекрутинг
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Kuopio, Финляндия, 70210
- Рекрутинг
- Kuopio University Hospital
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Франция, 69310
- Рекрутинг
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Seoul, Южная Корея, 02841
- Рекрутинг
- Korea University Anam Hospital
-
Suwon, Южная Корея, 16499
- Рекрутинг
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Южная Корея, 48108
- Рекрутинг
- Inje University-Haeundae Paik Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Экспериментальный: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Экспериментальный: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Временное ограничение: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Временное ограничение: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Временное ограничение: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Временное ограничение: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Временное ограничение: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Временное ограничение: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Временное ограничение: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Временное ограничение: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Временное ограничение: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Временное ограничение: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Временное ограничение: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Патологические процессы
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Заболевания матки
- Заболевания половых органов, Женский
- Неопластические процессы
- Генитальные Новообразования, Женщины
- Новообразования матки
- Патологические состояния, признаки и симптомы
- Метастаз новообразования
- Новообразования эндометрия
- Синдром турко
- Пембролизумаб
Другие идентификационные номера исследования
- EIK1005-002
- 2026-525248-13-00 (Ктис)
- KEYNOTE-G56 (Другой идентификатор: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Другой идентификатор: Merck Sharp & Dohme LLC)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .